Plaque REgression With Cholesterol Absorption Inhibitor or Synthesis Inhibitor Evaluated by IntraVascular UltraSound

• Status: Completed
• Trial end date: 2014-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study was to evaluate the difference in the effect of coronary plaque regression (as measured by intravascular ultrasound [IVUS] imaging) between cholesterol absorption inhibitor and cholesterol synthesis inhibitor.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Kumamoto University
• Treatments: Atorvastatin; Atorvastatin Calcium; Ezetimibe

Criteria

Inclusion Criteria:

• Signed written informed consent,

• 30 to 85 years old,

• Plan to undergo PCI and LDL-C >= 100 mg/dL

Exclusion Criteria:

• Familial hypercholesterolemia

• Being treated with Zetia (Ezetimibe)

• Being treated with Fibrates

• Renal insufficiency (serum creatinine >= 2.0 mg/dl)

• Altered hepatic function (serum aspartate aminotransferase or alanine aminotransferase >= 3-folds of standard value in each institute)

• Undergoing hemodialysis or peritoneal dialysis

• Allergic to Lipitor and/or Zetia

• Severe underlying disease

• Lack of decision-making capacity

• Recognized as inadequate by attending doctor